Sponsored Events

Contract-Biotechnology.com is routinely participating in international partnering and conferences. The following event are sponsored by Contract-Biotechnology.com

The Microbiome Movement – Skin Health & Dermatology Summit  

September 10-12 | San Diego
Website: https://bit.ly/2NviFAY

The Microbiome Movement – Skin Health & Dermatology Summit will unite over 100 KOL’s, senior drug developers, cosmetic product developers & technology experts to harness the skin microbiome and accelerate the discovery, development & commercialization of dermatological therapeutics and the next-generation of cosmetics, founded on clinically validated data.

Join the likes of L’Oreal, Unilever, Estee Lauder, Matrisys Bioscience, the FDA, Naked Biome, Amway and 100+ experts in the field this September, to better understand the commercial potential of the skin microbiome for your business.

Take a look at the event guide now to see the finalized program and meet the speakers: https://bit.ly/2NviFAY

September 25-27, 2018 Seville, Spain https://www.biospain2018.org/

BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.000) and companies participating (+800). 34% of our delegates came from outside of Spain.

BIOSPAIN is organized by ASEBIO, the Spanish Bioindustry Association and each edition is co-organized by a local institution from the host city/region. On the 2018 edition, Biospain is co-organized by the Government of Andalucia through IDEA Agency. 

Some data about the 8th edition of BIOSPAIN held in Bilbao (Spain) were:

·         46 investors have attended the eigth edition of Biospain, including Edmond de Rothschild Investment Partners, Forbion, Johnson & Johnson Innovation, Novartis Venture Fund, Ysios Capital Partners, Caixa Capital Risc and Cross Road Biotech. 

·         Biospain 2016 further consolidates its position as the fifth biggest event for business meetings, with 2,970 one-to-one meetings taking place.

·         The event was attended by 1,750 individuals and 701 entities from 29 countries, meaning there was an international presence of 28%.

·         233 exhibitors came together for the event, with more exhibition space than at the previous edition.  

·         84.81% of survey respondents claimed to have identified real business opportunities. 

Immuno-Oncology Conference 26 – 27 September 2018 London, UK http://www.immuno-oncology-conference.com/contrbioWL

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.  In the programme: Targeting immune checkpoints with Humabody VH therapeutics; Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy; Tumour mutation burden and the potential of its use as an indication of treatment choice; Unwanted immunogenicity and functionality testing of immuno-oncology drugs; New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology  

  For further details at http://www.immuno-oncology-conference.com/contrbioWL  #immunooncologysmi LinkedIn - SMi Pharma CONTACT: +44 (0)20 7827 6000  ldurneva@smi-online.co.uk

Biosimilars & Biobetters 26th - 27th September 2018 London, Uk 

http://www.biosimilars-europe.com/contractbiotech

The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK. Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market. After over a decade, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars. This is reflected in more tolerant legislation and an increased uptake of biosimilars across the globe.We are now entering a very exciting time, for over the next few years several originator patents are expiring, and we will see the next few waves of biosimilars enter the market. Will the biosimilar be a successful contender and spark a competitive environment or the originator dominate? Have we done enough to convince the payer, prescriber and patient to switch?Join us to hear experiences of key opinion leaders and evaluate market access, opportunities and commercialisation strategies with industry-thought experts.This event is CPD accredited.

Join Oxford Global’s 5^th Annual Drug Discovery USA Congress taking place on the 11-12 October 2018 in San Diego. Across the two days, over 40 expert speakers will provide you with insights into the latest technological innovations and strategic approaches in drug discovery and drug chemistry. View Agenda: https://bit.ly/2MIXuM8

The American biopharmaceutical research sector has been a world leader in the development of new medicines over the past 30 years and it continues to drive biopharmaceutical innovation. Our conference delivers an extensive look across the development process: from drug discovery innovation and strategies to computational chemistry and informatics for drug design.The conference will feature over 40 presentations from leading heads of the pharmaceutical industry and ensures you will benefit from the latest case studies and high level scientific debate. Topic discussion ranges across the latest validation and optimisation strategies in neuroscience, cardiology and oncology. Further talks look at approaches to phenotypic and genomic drug discovery design, as well as novel approaches to drug design: AI-based design, DNA Encoded Libraries and protein-protein interactions.Include 4 Streams:

• Day 1 Stream 1: Drug Discovery Innovation and Strategies
• Day 2 Stream 1: Phenotypic and Genomic Drug Discovery
• Day 1 Stream 2: Computational Chemistry and Informatics for Drug Discovery
• Day 2 Stream 2:
  • Part 1: Novel Approaches to Drug Design
  • Part 2: DNA Encoded Libraries

Orphan Drugs and Rare Diseases Conference 17 – 18 October 2018 London, UK http://www.orphandrugs.co.uk/contrbioWL

SMi’s Orphan Drugs and Rare Diseases Conference bringing together regulatory agencies, pharmaceutical companies, non-profit organisations and orphan drugs developers to construct an agenda that addresses the driving economic factors, policies and issues that will affect the development of orphan drugs globally including commercialisation, policies, reimbursement, and pricing. Discuss the pricing and reimbursement of orphan drugs; Understand the challenges of patient recruitment and patient-centric research; Hear the MHRA’s perspective on benefit-risk assessment in rare diseases; Explore the clinical development of orphan drugs for rare disease; Gain insight into potential synergies between regulators and assessors. Amongst speakers: Carina Schey - University of Groningen; Xavier Ortega – Minoryx; Nigel Nicholls - BioMarin Europe; Yolanda Barbachano – MHRA; Michale Bouskila-Chubb – Healx and many others! Post-conference workshop (19 October) on Working together for HTA in rare diseases - a step too far or the way forward?

Further details at http://www.orphandrugs.co.uk/contrbioWL  #smiorphandrugs CONTACT:+44 (0)20 7827 6000 ldurneva@smi-online.co.uk

SMi’s 5th Annual Biosimilars USA , 14th - 15th November 2018 New Jersey, USA

http://www.biosimilars-usa.com/contractbiotech

Building on the success of previous events, SMi proudly announces the return of its 5th Annual Biosimilars USA Conference, taking place in New Jersey on the 14th and 15th November 2018.This fifth annual event will gather a global audience of biosimilar experts and industry-thought leaders to discuss biosimilar manufacturing and commercialization considerations specific to the U.S. Fresh from the press: On March 7th, 2018, the U.S.-FDA’s Commissioner, Scott Gottlieb, MD, announced that Biosimilar medicines are now a top priority for the FDA. Join us this November to learn how to take advantage of the FDA’s focus on biosimilars, accelerate your biosimilar pipeline and achieve FDA approval. Hear from a selection of carefully handpicked keynote addresses and case studies presented to you by top manufacturing and leading distributors of market approved biosimilars, as they offer a unique insight into the areas of manufacturing, commercialization, device design, uptake, switching, interchangeability, and regulations.

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS.Tuesday 25th September 2018, Copthorne Tara Hotel, Central London, UK.This event is CPD accredited. #SMiBioSimUSA

International Neurology Conference is going to be held during December 03-05, 2018, Valencia, Spain. Neurology-2018 

Participants has a wide choice of selection in the scientific sessions please see the link: https://neurology.madridge.com/themes.php.

Neurology-2018 conference includes Plenary lectures, Keynote lectures and short courses by eminent personalities from around the world in addition to contributed papers both oral and poster presentations. Abstract submission: https://neurology.madridge.com/guidelines.php 

 For list Committee: https://neurology.madridge.com/committee.php. For list of presenters: Won-Myong Bahk, The Catholic University of Korea.  Bo-Hyun Yoon, Naju National Hospital, Sang-Yeol Lee, MD, PhD. Department of Psychiatry, College of Medicine, Wonkwang ,University Hospital ,Duk-In Jon, Hallym University, Moon-Doo Kim, Jeju National University,  Kwang Huen Lee, Dongguk UniversityBeomwoo, Konkuk University. Young-Min Park, Inje University College of Medicine.Young-Joon Kwon Soonchunhyang University. Dae-Bo Lee, National Forensic Hospital  Andrew Collins, UCL Institute of Neurology, UK. Min Zhuo Xian Jiaotong University, China Himanshu Agarwal, All India Institute of Medical Sciences, India Miroslava Navratilova, Czech Republic, Fatemeh Ehsani, Semnan University of Medical Sciences, Iran Jun Hwi Cho, Kangwon National University. Elkaoui habiba, University Ibn Tofail, Morocco  Hajar benmhammed, Morocco  Dilshoda Akramova , Tashkent Medical Academy,Eric gueumekane bila lamou, UCAD- Senegal 

To arrange a meeting, please contact us and we will arrange a mutually convenient time.